TransCon PTH brings benefits for up to 1 year in PATHway trial
TransCon PTH treatment continues to show benefits for up to a year in people with hypoparathyroidism, helping them achieve normal blood calcium levels and reducing the need for conventional therapy. That’s according to new data from PATHway (NCT04701203), a Phase 3 clinical trial wherein Ascendis Pharma…